SCHEMBL15904219

SCHEMBL15904219

CCOCCC(C)CC(CN)CC(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 2/20 0.54
CACNB3 P54284 1/20 0.54
CACNA1C Q13936 1/20 0.54
PGR P06401 1/20 0.54
ADRA1A P35348 1/20 0.54
HTR2B P41595 1/20 0.54
CACNA2D2 Q9NY47 1/20 0.54
GABRR1 P24046 2/20 0.32
LMNA P02545 1/20 0.32
GABRP O00591 2/20 0.32
GABRD O14764 2/20 0.32
GABRA1 P14867 2/20 0.32
GABRB1 P18505 2/20 0.32
GABRG2 P18507 2/20 0.32
GABRB3 P28472 2/20 0.32
GABRA5 P31644 2/20 0.32
GABRA3 P34903 2/20 0.32
GABRA2 P47869 2/20 0.32
GABRB2 P47870 2/20 0.32
GABRA4 P48169 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3116502 1.00 CACNA2D1 (0.54) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL1913495 1.00 CACNA2D1 (0.54) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL6056428 0.91 CACNA2D1 (0.54) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL1913699 0.91 CACNA2D1 (0.54) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL3122038 0.91 CACNA2D1 (0.54) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL3121623 0.86 CACNA2D1 (0.53) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL3121915 0.86 CACNA2D1 (0.53) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL1914024 0.86 CACNA2D1 (0.53) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL1913873 0.86 CACNA2D1 (0.53) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL1914025 0.86 CACNA2D1 (0.53) CACNA2D1CACNB3CACNA1CPGRADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2948149-A2 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT Aldeyra Therapeutics, Inc. (US) 2015-12-02 EP claimed
WO-2014116836-A2 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDEXA THERAPEUTICS, INC. (US) 2014-07-31 WO claimed
US-20250127733-A1 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDEYRA THERAPEUTICS, INC. 2025-04-24 US disclosed
CN-117045653-A Diseases and treatments associated with toxic aldehydes 奥尔德拉医疗公司 2023-11-14 CN disclosed
CN-111135171-B Diseases and treatments associated with toxic aldehydes 奥尔德拉医疗公司 2023-09-08 CN disclosed
US-11701331-B2 Toxic aldehyde related diseases and treatment ALDEYRA THERAPEUTICS, INC. (US) 2023-07-18 US disclosed
US-20210275469-A1 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDEYRA THERAPEUTICS, INC. 2021-09-09 US disclosed
US-11007157-B2 Toxic aldehyde related diseases and treatment ALDEYRA THERAPEUTICS, INC. (US) 2021-05-18 US disclosed
US-10588874-B2 Toxic aldehyde related diseases and treatment ALDEYRA THERAPEUTICS, INC. (US) 2020-03-17 US disclosed
US-20190247334-A1 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDEXA THERAPEUTICS, INC. 2019-08-15 US disclosed
EP-2948149-A2 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT Aldeyra Therapeutics, Inc. (US) 2015-12-02 EP disclosed
WO-2014116836-A2 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDEXA THERAPEUTICS, INC. (US) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210275469-A1 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDH1A2, ALDH2, ALDH1A1 CACNA2D1 4227/4885CACNB3 2185/4885CACNA1C 3005/4885
US-20190247334-A1 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDH1A2, ALDH2, ALDH1A1 CACNA2D1 4227/4885CACNB3 2185/4885CACNA1C 3005/4885
US-11007157-B2 Toxic aldehyde related diseases and treatment ALDH1A2, ALDH2, ALDH1A1 CACNA2D1 4227/4885CACNB3 2185/4885CACNA1C 3005/4885
US-10588874-B2 Toxic aldehyde related diseases and treatment ALDH1A2, ALDH2, ALDH1A1 CACNA2D1 4227/4885CACNB3 2185/4885CACNA1C 3005/4885
US-20250127733-A1 TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT ALDH1A2, ALDH2, ALDH1A1 CACNA2D1 4227/4885CACNB3 2185/4885CACNA1C 3005/4885
US-11701331-B2 Toxic aldehyde related diseases and treatment ALDH1A2, ALDH2, ALDH1A1 CACNA2D1 4227/4885CACNB3 2185/4885CACNA1C 3005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.